Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTN - Palatin Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: serndip who wrote (114)	7/19/2006 6:31:34 PM
From: rareearth42	Read Replies (1) \| Respond to of 142

I think the PTN price has fallen recently because of the NSTK results; the FDA gave them a non-approvable letter for generic nasal calcitonin because of some theoretical allergic interaction between a preservative and the drug substance, as I understand it. Some investors are worried that the same thing could happen to PTN. I think their concerns are over-blown, because PTN can specifically assess this and avert the problem before phase 3 testing. Right now is a pretty good time to buy, with PTN selling at a dollar and change. When the phase 2b is very successful and the stock price is $5-10, they'll do a secondary to help support phase 3 and subsequent marketing together with KG, but it will be too late to get the real bargain. RE42